| Date | Title | Description |
| 07.05.2026 | Debut and Oterra Join Forces to Replace Red 40 with Precision Fermentation Colors | US biotech company Debut and Danish natural color supplier Oterra have announced a multi-million-dollar collaboration to develop a fermentation-derived alternative to Red 40, one of the most commonly used synthetic food colorings in the Uni... |
| 06.05.2026 | Oterra to scale natural alternative to Red 40 food dye in new partnership | Listen to the article 3 min
This audio is auto-generated. Please let us know if you have feedback. Dive Brief:
Ingredient supplier Oterra has entered a multi-million dollar partnership with biotech firm Debut to scale an alternative to Red ... |
| 06.05.2026 | Debut and Oterra partner to develop and scale biotech alternative to Red 40 for food and beverage | Debut and Oterra partner to develop and scale biotech alternative to Red 40 for food and beverage
Wed, May 06, 2026 14:29 CET Report this content
SAN DIEGO, USA & HOERSHOLM, Denmark, May. 6, 2026 — Debut, a pioneer in AI-powered biotech... |
| 22.04.2026 | Funding dip for alt protein fermentation signals shift from promise to proof | Funding for fermentation startups in alt protein—spanning everything from mycoprotein to recombinant casein—fell from $632 million in 2024 to $357 million in 2025, according to a new report from The Good Food Institute (GFI). But for startu... |
| 13.09.2025 | /C O R R E C T I O N -- Mars/ | In the news release, Mars Snacking and Unreasonable Group Welcome Fourteen New Ventures to Unreasonable Food™, issued 11-Sep-2025 by Mars over PR Newswire, we are advised by the company that the release has been updated to include the full ... |
| 11.09.2025 | Mars Snacking and Unreasonable Group Welcome Fourteen New Ventures to Unreasonable Food™ | As an international network, Unreasonable Food is uniquely positioned to scale high-growth ventures dedicated to creating a more sustainable food system.
NEW YORK, Sept. 11, 2025 /PRNewswire/ -- Today, as part of the Unreasonable Food™ coll... |
| 27.08.2025 | Debut: $20 Million Raised For AI Ingredient Discovery Platform | Debut, a leader in biotech beauty, has secured $20 million in investment to expedite the development of its proprietary, AI-powered ingredient discovery platform, aiming to advance innovations in skin longevity and expand its formulation bu... |
| 26.03.2025 | Differential Bio emerges from stealth with virtual scaleup platform for bioprocess optimization | Scaling bioprocesses is “notoriously slow and prohibitively expensive,” says Differential Bio CEO Christian Spier. “We’re here to change that.”
Emerging from stealth this week with €2 million ($2.2 million) in pre-seed funding, the Munich-b... |
| 05.03.2025 | The Future of Food: Embracing Innovation in Plant-Based Production and Sustainable Ingredients | The food industry is at a crossroads. The demand for plant-based products is surging. Consumers are more conscious than ever about what they eat. They want healthier options. They want sustainability. This shift is not just a trend; it’s a ... |
| 03.03.2025 | Debut Develops Animal-Free Carmine Pigment Using Proprietary Biotechnology | Debut, a US company producing biotech ingredients for the beauty industry, has announced a breakthrough in the development of animal-free carmine.
Carmine is an intense red pigment derived from the cochineal beetle, and is widely used in be... |
| 20.05.2024 | SynBioBeta 2024: From novel hosts to ‘tricking’ cells to be more productive… addressing the ‘scale-cost paradox’ in biomanufacturing | Since insulin produced by genetically engineered bacteria—rather than the pancreases of slaughtered animals—was first approved in 1982, the market for ‘biomanufactured’ products produced by microbial, animal, or plant cells has grown rapidl... |
| 22.04.2024 | He Had a Side Hustle Driving for Uber When a Passenger Gave Him $100,000 — Now His Company Is On Track to Solve a Billion-Dollar Problem Joshua Britton is the founder and CEO of Debut, a biotechnology... | - |
| 29.12.2023 | 2023 in review: Beyond Meat in ‘survival’ mode, ‘jaundiced’ indoor ag investors, AI in every pitchdeck… | 2023 has been a tough year for agrifoodtech startups, with high interest rates, inflation, fundraising challenges, banking scares, and souring investor sentiment in sectors from indoor ag to alt proteins, prompting pivots, layoffs, and busi... |
| 16.11.2023 | Material Impact announces $352m materials science fund: ‘You can trace back disruptive innovation in almost any industry to an underlying advance in material science’ | Boston-based venture firm Material Impact has announced Material Impact Fund III, a $352 million fund to back inception-stage companies developing products enabled by innovations in materials science.
The firm, which has $800 million in ass... |
| 20.10.2023 |
Debut Finds $40M In New Funding
| San Diego-based Debut, which is applying synthetic biology to the fragrance industry, says it has raised $40M in a Series B funding round. The company said the funding was led by BOLD, the venture capital fund of L'Oreal. Debut says it is d... |
| 19.10.2023 | Debut Closes $40M in Series B Funding | Debut, a San Diego, CA-based vertically integrated synthetic biology company focused on beauty, raised $40M in Series B funding.
The round was led by Bold.
The company intends to use the funds to accelerate the development of bio-identical ... |
| 02.06.2023 | Debut Raises $34M in Series B Funding | Billy Economou of BE Studios and Ariba Alvi of Debut
Debut, a San Diego, CA-based vertically integrated synthetic biology company creating active ingredients in beauty, raised $34M in Series B funding.
The round was led by BOLD with partici... |
| 02.06.2023 | Debut Biotech raises $34M in funding to expand their operations are reach | - |
| 09.09.2022 | Debut Launches its Bio2Consumer™ Platform to Become the Leader in Vertically Integrated Synthetic Biology | "For synthetic biology to have a true impact on humanity, it needs to be commercialized, integrated into global supply chains, and ultimately embraced by consumers." - Debut CEO Joshua Britton
SAN DIEGO (PRWEB) September 09, 2022
... |
| 28.07.2022 | Debut Biotech and DIC to Advance and Scale the Biomanufacturing of Sustainable Red Colors for Food, Nutrition, and Cosmetic Industries | “Companies need access to the types of ingredients — including red colorings — that consumers demand... Synthetic biology is allowing access to incredible products that are only found in minute quantities in plants and animals.” - Joshua Br... |
| 07.07.2022 | Debut Biotech and GeneChem to Develop Rare Ingredients for Use in Infant Formula and Nutritional Products | "Our hybrid biomanufacturing approach enables commercial-level production of rare ingredients in a way that no other processes can" - Joshua Britton, CEO, Debut Biotech
SAN DIEGO (PRWEB) July 07, 2022
Debut Biotechnology, Inc., a ... |
| 02.02.2022 | BREAKING: Tierra Biosciences launches “proteins-on-demand” platform to speed up synbio engineering | Synthetic biology company Tierra Biosciences has officially launched its “proteins-on-demand” e-commerce portal where synbio scientists and researchers get custom proteins synthesized, validated, and shipped to them via a single interface.
... |
| 17.09.2021 | Debut Biotech is creating next-gen ingredients through ‘cell-free biomanufacturing’ | With climate change and its environmental consequences upon us, many companies are turning to more ‘natural’ alternatives to the chemical-based ingredients commonly used in food, beverages, cosmetics, and therapeutics.
One such company is S... |
| 12.08.2021 | Debut Biotech makes its entrance with a $22M series A for cell-free biomanufacturing facility | Debut Biotech wants to be the next big biomanufacturer, and the two-year-old startup thinks cell-free enzymes are the way forward. The company raised $22.6 million in series A funds Thursday to prove that out.
However, commonplace biomanufa... |
| 12.08.2021 | Debut Biotech Lands $22.6M Series A |
SAN DIEGO, CA, Debut Biotech, a next generation biomanufacturing platform harnessing cell-free enzymes, today announced its $22.6 million Series A financing, led by Material Impact.
>> Click here for more funding data on Debut Biot... |
| 12.08.2021 | Debut Biotech makes its entrance with a $22M series A for cell-free biomanufacturing facility | Debut Biotech wants to be the next big biomanufacturer, and the two-year-old startup thinks cell-free enzymes are the way forward. The company raised $22.6 million in series A funds Thursday to prove that out.
The fresh proceeds will help f... |
| 12.08.2021 | Debut Biotech Raises $22.6M in Series A Funding | Debut Biotech, a San Diego, CA-based developer of a biomanufacturing platform harnessing cell-free enzymes, raised $22.6M in Series A financing.
The round was led by Material Impact with participation from Cultivian Sandbox Ventures, Fine S... |
| 12.08.2021 | Debut Biotech Raises $22.6M Series A to Commercialize High-Value Ingredients from Proprietary Cell-Free Biomanufacturing Platform | - |
| 12.08.2021 | Debut Biotech Raises $22.6M Series A to Commercialize High-Value Ingredients from Proprietary Cell-Free Biomanufacturing Platform | By overcoming the limitations of cell-based fermentation, Debut Biotech produces high-value ingredients rapidly and more sustainably.
SAN DIEGO (PRWEB) August 12, 2021
Debut Biotech, a next generation biomanufacturing platform harnessing ce... |
| 28.07.2021 | Debut Biotech and DIC Enter into Joint Development to Biomanufacture Natural, Sustainable Colors | Debut Biotech's new approach for the production of a range of color ingredients will have applications across many industries, from food and cosmetics to health products.
SAN DIEGO (PRWEB) July 28, 2021
Today, Debut Biotech, a next generati... |
| 20.07.2021 | Debut Biotech Partners with Battelle Team to Transform Plastic Waste into High-Value Resources under DARPA’s ReSource Program | With our cell-free method, we’re able to turn common materials and feedstocks — in this case, plastics and other waste materials — into high value outputs with a fraction of the resources.
SAN DIEGO (PRWEB) July 20, 2021
Today, Debut Biotec... |
| 06.05.2021 | Debut Biotech Partners with DSM to Biomanufacture High Value Natural Ingredients | "Debut Biotech's cell-free platform has the ability to transform low-value bio-renewable materials into high-value specialty chemicals."
SAN DIEGO (PRWEB) May 06, 2021
Debut Biotech, a cell-free biomanufacturing platform, today an... |
| 23.03.2021 | Next gen cell-free biomanufacturing could unlock opportunities to biosynthesize far wider set of natural ingredients, claims startup | Right now, says Debut Bio’s co-founder and CEO Dr Joshua Britton, you can extract colors, flavors, and bioactives from plants, which can be expensive, inefficient, and not very sustainable if you’re devoting acres of agricultural land to gr... |
| 28.08.2020 | From Francis Ford Coppola to foodtech: FTW Ventures’ Brian Frank on latest fund | San Francisco-based FTW Ventures describes itself as the “secret force” behind some big changes coming to the food system. This week it announced a new $4 million agrifoodtech fund, which has already made five investments and is targeting 1... |
| 15.01.2020 | Debut Biotechnology Secures $2.6 Million In Seed Funding | UC-Irvine spinout Debut Biotechnology announced it has raised $2.6 million in a seed round of funding
Debut Biotechnology, a spinout of UC-Irvine that is advancing scalable cell-free biomanufacturing, announced it has raised $2.6 million in... |
| 07.01.2020 | Debut Biotechnology Raises $2.6M in Seed Funding | Debut Biotechnology, a UC-Irvine spinout that is advancing scalable cell-free biomanufacturing, closed a $2.6M seed funding round.
The round was led by KdT Ventures, with participation from Better Ventures, FTW Ventures, and SpringTide Vent... |
| 07.01.2020 | Daily funding roundup - January 7th, 2020 | TeleVet closed $2M; Ripple Science and OncoLens raised $2.5M; Debut Biotechnology landed $2.6M
TeleVet: TeleVet platform is connecting veterinary clinics to clients. TeleVet has raised $2 million in seed funding co-led by Dundee VC and Merc... |
| - | Debut Biotech | “Not another synthetic biotech company. We use science, strategy and creativity to build big businesses that put humanity ahead.” |
